newsfilter
← Latest News
Business Wire·

Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced